Ribo Newsroom
-
Ribo Life Science (06938.HK) Successfully Lists on the Main Board of the Hong Kong Stock ExchangeRibo Life Science (06938.HK) Successfully Lists on the Main Board of the Hong Kong Stock ExchangeJanuary 9, 2026 -
Ribo Receives Phase II Clinical Approval for ApoC3-targeting siRNA drug RBD5044 in ChinaRibo Receives Phase II Clinical Approval for ApoC3-targeting siRNA drug RBD5044 in ChinaJanuary 23, 2026 -
Ribo Presents Kidney-Targeted Delivery Data at ASN Kidney Week 2025Ribo recently presented a poster at the ASN Kidney Week in Texas, showcasing the kidney-targeted delivery of siRNA using its RiboPepSTAR™ peptide conjugates.December 4, 2025 -
Ribo Granted EMA Orphan Drug Designation for siRNA Therapeutic RBD1016 for Hepatitis Delta Virus (HDV) InfectionRibo and Ribocure today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to RBD1016 for the treatment of Hepatitis D Virus (HDV) infection.October 24, 2025 -
Ribo Showcases New Clinical Data from Leading siRNA Programs at ESC 2025, Underscoring Significant Progress and Achievements in Advancing Cardiovascular TherapiesRibo and Ribocure Pharmaceuticals AB presented four key scientific findings at the 2025 European Society of Cardiology (ESC) Congress in Madrid, Spain, underscoring significant progress in siRNA-based cardiovascular therapeutics pipeline.September 10, 2025 -
Ribo Secures Series E Funding to Accelerate Global siRNA Therapeutics StrategyRibo secures series E funding to accelerate global siRNA therapeutics strategyJuly 21, 2025